Results 171 to 180 of about 41,494 (257)

The Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Ryu DG, Yu F, Yoon KT, Liu H, Lee SS.
europepmc   +1 more source

Muscarinic acetylcholine receptors

Japanese Journal of Pharmacology, 1978
Kunio Takeyasu, Shuji Uchida, Hiroshi Yoshida, Norifumi Yonehara   +3 more
openaire   +2 more sources

The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome

British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1049-1063, April 2025.
Big data in drug development may not satisfactorily address the demands of precision medicine in a rare disease population, making the use of smaller clinical trials necessary. Consequently, the use of innovative design and analysis of these clinical trials using model‐informed approaches have become indispensable.
Ene I. Ette, Emmanuel O. Fadiran, Christopher Missling, Edward Hammond   +3 more
wiley   +1 more source

A Clinically Oriented Review of New Antipsychotics for Schizophrenia. [PDF]

Neuropsychiatr Dis Treat
Luca M, Luca A, Serretti A.
europepmc   +1 more source

Toll‐like receptor 4 deficiency ameliorates experimental ileitis and enteric neuropathy: Involvement of nitrergic and 5‐hydroxytryptaminergic neurotransmission

British Journal of Pharmacology, Volume 182, Issue 8, Page 1803-1822, April 2025.
Abstract Background and Purpose Inflammatory bowel disease (IBD) patients display genetic polymorphisms in toll‐like receptor 4 (TLR4) genes, contributing to dysregulate enteric nervous system (ENS) circuits with increased levels of 5‐HT and alteration of the neuroimmune crosstalk.
Sofia Faggin, Silvia Cerantola, Valentina Caputi, Angela Tietto, Elena Stocco, Annalisa Bosi, Alessandra Ponti, Antonella Bertazzo, Veronica Macchi, Andrea Porzionato, Edoardo V. Savarino, Cristina Giaroni, Maria Cecilia Giron   +12 more
wiley   +1 more source

A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction. [PDF]

Int J Mol Sci
Kallinikas G, Haronis G, Kallinika E, Kozyrakis D, Rodinos E, Filios A, Filios P, Mityliniou D, Safioleas K, Zarkadas A, Bozios D, Karmogiannis A, Konstantinopoulos V, Konomi AM, Ektesabi AM, Tsoporis JN.   +15 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Adiponectin signaling regulates urinary bladder function by blunting smooth muscle purinergic contractility. [PDF]

JCI Insight
Luo Z, Wu A, Robson S, Alper SL, Yu W.
europepmc   +1 more source

Characterization of the Molecular Mechanisms Underlying Lurasidone‐Induced Acute Manic Episodes in Bipolar Depression: A Network Pharmacology and Molecular Docking Approach

CNS Neuroscience &Therapeutics, Volume 31, Issue 4, April 2025.
This study is the first to systematically explore the molecular mechanisms underlying lurasidone‐induced acute manic episodes in people with bipolar depression using network pharmacology and molecular docking approaches. Our bioinformatics and computational analyses demonstrated that lurasidone may regulate the serotonergic synapse signaling pathway by
Chao Li, Lei Yang, Qiuyu Zhang, Ying Zhang, Ranli Li, Feng Jia, Lina Wang, Xiaoyan Ma, Hongjun Tian, Chuanjun Zhuo   +9 more
wiley   +1 more source

Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials. [PDF]

BMC Psychiatry
Mohammed HE, Gomaa MA, Khalifa YM, Shawky AA.   +3 more
europepmc   +1 more source